The Ministry of Health, Labor and Welfare (MHLW) on December 12 presented a draft outline of the FY2026 drug pricing…
BUSINESS
Fuji Pharma Kicks Off Japan PIII for Alyssa in Endometriosis
Fuji Pharma said on July 25 that it is launching a domestic PIII study for its dysmenorrhea drug Alyssa (estetrol + drospirenone) for the treatment of pain associated with endometriosis.The company licensed the drug from Hungary-based Gedeon Richter. In Japan,…
To read the full story
Related Article
- Japan Panel Clears Amgen’s TED Med, Rexulti for Alzheimer’s Agitation and More
August 28, 2024
- Eisai’s ALS Therapy, Amgen’s TED Drug Up for Review on Aug. 26
August 19, 2024
- Fuji Pharma/M3’s Dysmenorrhea Drug Filed in Japan, 2024 Rollout Targeted
October 19, 2023
- Fuji Pharma/M3’s Dysmenorrhea Drug Hits Main PIII Goal; 2024 Launch Eyed
February 10, 2023
- Fuji Pharma, M3 Join Hands on Dysmenorrhea Med in Japan
November 13, 2020
BUSINESS
- Oncolys Files Telomelysin in Japan, Eyes API Manufacturing Expansion in Asia
December 16, 2025
- Eisai Flags Nitrosamine Found in Merislon, Says Supply to Continue
December 16, 2025
- Mochida to Bring in Morning Sickness Drug from Canada’s Duchesnay
December 16, 2025
- Global PIII Trial Halted for Arcus-Partnered TIGIT Drug: Taiho
December 16, 2025
- Vyvdura Now Available in Prefilled Syringe: Argenx Japan
December 16, 2025
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…